Information and calculation tools by Rachid Asen. Not investment advice or research.

Disclaimer. Information tool. Compiles data published by NSE and BSE and calculations from the exchanges' published ESM and ASM criteria. Prices are end-of-day, not live: updated each evening after trading ends. Ethical business criteria are matched by AI, which can make mistakes; this is a criteria match, not a certification, fatwa, rating or advice. Check the company's filings. Not investment advice, research or a recommendation to buy, sell or hold any security; not SEBI-registered as an Investment Adviser or Research Analyst. Calculated dates are the earliest a security could become eligible; inclusion, stage changes and exit are decided solely by the exchanges. ESM, ASM and GSM shortlisting are surveillance measures and not an adverse action against the company. Data may be delayed or inaccurate; verify with the exchange.

AlphaSurveillanceby Rachid AsenNotebookDiscussionConnect AISign in
Market closedIST

Elantas Beck India Limited

ELANTAS (NSE) · ELANTAS (BSE 500123) · ISIN INE280B01018 · Specialty Chemicals · Est. 1956 · listed 2026 · website

Not on any surveillance list

In Q2 FY27 (quarter to 30 September 2026, standalone), revenue was ₹265.31 cr and profit after tax ₹45.55 cr. Revenue was 22.5% higher than in Q2 FY26.

Quarterly results

Quarterly results, ₹ crore (as filed)
QuarterRevenueProfit after taxEPS (₹)Filed
Q2 FY27 standalone₹265.31 cr₹45.55 cr57.4528 Oct 2026
Q1 FY27 standalone₹283.39 cr₹70.86 cr89.394 Aug 2026
Q4 FY26 standalone₹222.17 cr₹31.08 cr39.2112 May 2026
Q3 FY26 standalone₹215.2 cr₹39.37 cr49.6624 Feb 2026
Q2 FY26 standalone₹216.55 cr₹36.26 cr45.744 Nov 2025

Shareholding

Shareholding pattern, Sep 2026
PromoterFIIDIIPublic
75.00%0.05%12.53%25.00%

Latest filings

Other companies in Specialty Chemicals

Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.

Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.